帕博利珠单抗联合乐伐替尼治疗一名接受血液透析的转移性肾细胞癌患者。
Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis.
作者信息
Yamashita Shimpei, Kawabata Hiroki, Iwahashi Yuya, Muraoka Satoshi, Wakamiya Takahito, Kojima Fumiyoshi, Kohjimoto Yasuo, Murata Shin-Ichi, Hara Isao
机构信息
Department of Urology Wakayama Medical University Wakayama Japan.
Department of Pathological Diagnosis Wakayama Medical University Wakayama Japan.
出版信息
IJU Case Rep. 2025 Mar 9;8(3):223-226. doi: 10.1002/iju5.70011. eCollection 2025 May.
INTRODUCTION
There is no clear evidence of the safety and efficacy of pembrolizumab plus lenvatinib combination therapy in patients on hemodialysis. This is the first report of a patient on hemodialysis to receive this combination therapy for metastatic renal cell carcinoma.
CASE PRESENTATION
A 60-year-old man on hemodialysis had cT3bN1M0 unclassified renal cell carcinoma. He received the combination therapy of pembrolizumab plus lenvatinib. Although the dose of lenvatinib was halved to 10 mg/day due to Grade 3 thrombocytopenia, 6 months later, the volumes of the primary lesion and lymph node metastasis were remarkably reduced.
CONCLUSION
Our case report suggests the feasibility of the combination therapy of pembrolizumab plus lenvatinib for patients with metastatic renal cell carcinoma who are undergoing hemodialysis.
引言
目前尚无明确证据表明帕博利珠单抗联合乐伐替尼的联合疗法对血液透析患者的安全性和有效性。本文首次报道了一名接受血液透析的患者接受该联合疗法治疗转移性肾细胞癌的病例。
病例介绍
一名60岁接受血液透析的男性患有cT3bN1M0未分类肾细胞癌。他接受了帕博利珠单抗联合乐伐替尼的联合治疗。尽管由于3级血小板减少症，乐伐替尼的剂量减半至10毫克/天，但6个月后，原发灶和淋巴结转移灶的体积显著减小。
结论
我们的病例报告表明，帕博利珠单抗联合乐伐替尼的联合疗法对于正在接受血液透析的转移性肾细胞癌患者是可行的。
Zotero 插件